Serum protein N-glycan alterations of diethylnitrosamine-induced hepatocellular carcinoma mice and their evolution after inhibition of the placental growth factor
详细信息 查看全文
- 作者：Bram Blomme (1)
Femke Heindryckx (1)
Jean Marie Stassen (2)
Anja Geerts (1)
Isabelle Colle (1)
Hans Van Vlierberghe (1) - 关键词：Glycomics ; Hepatocellular carcinoma ; Diethylnitrosamine ; c ; ets ; 1 protein ; Angiogenesis inhibitors
- 刊名：Molecular and Cellular Biochemistry
- 出版年：2013
- 出版时间：2 - January 2013
- 年：2013
- 卷：372
- 期：1
- 页码：199-210
- 全文大小：760KB
- 参考文献：1. Nordenstedt H, White DL, El-Serag HB (2010) The changing pattern of epidemiology in Hepatocellular carcinoma. Dig Liver Dis 42(Suppl 3):S206–S214 CrossRef
2. Sherman M (2005) Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 25:143-54 CrossRef
3. Piccinino F, Sagnelli E, Pasquale G, Giusti G (1986) Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 2:165-73 CrossRef
4. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R (2004) Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 10:429-34 CrossRef
5. Liu XE, Desmyter L, Gao CF et al (2007) N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology 46:1426-435 CrossRef
6. Xu J, Yun X, Jiang J et al (2010) Hepatitis B virus X protein blunts senescence-like growth arrest of human hepatocellular carcinoma by reducing Notch1 cleavage. Hepatology 52:142-54 CrossRef
7. Shim JK, Lee YC, Chung TH, Kim CH (2004) Elevated expression of bisecting / N-acetylglucosaminyltransferase-III gene in a human fetal hepatocyte cell line by hepatitis B virus. J Gastroenterol Hepatol 19:1374-387 CrossRef
8. Yanagi M, Aoyagi Y, Suda T, Mita Y, Asakura H (2001) / N-Acetylglucosaminyltransferase V as a possible aid for the evaluation of tumor invasiveness in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 16:1282-289 CrossRef
9. Goldman R, Ressom HW, Varghese RS et al (2009) Detection of hepatocellular carcinoma using glycomic analysis. Clin Cancer Res 15:1808-813 CrossRef
10. Kang R, Saito H, Ihara Y et al (1996) Transcriptional regulation of the / N-acetylglucosaminyltransferase V gene in human bile duct carcinoma cells (HuCC-T1) is mediated by Ets-1. J Biol Chem 271:26706-6712 CrossRef
11. Ko J, Miyoshi E, Noda K et al (1999) Regulation of the GnT-V promoter by transcription Ets-1 in various cancer cell lines. J Biol Chem 274:22941-2948 CrossRef
12. Sato Y (2001) Role of ETS family transcription factors in vascular development and angiogenesis. Cell Struct Funct 26:19-4 CrossRef
13. Wernert N, Raes MB, Lassalle P et al (1992) c-ets1 proto-oncogene is a transcription factor expressed in endothelial cells during tumor vascularization and other forms of angiogenesis in humans. Am J Pathol 140:119-27
14. Yang B, Hauser C, Henkel G et al (1996) Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets-1 and c-Ets-2. Moll Cell Biol 16:538-47
15. Cowley D, Graves B (2000) Phosphorylation represses Ets-1 DNA binding by reinforcing autoinhibition. Genes Dev 14:366-76
16. Pufall M, Lee G, Nelson M et al (2005) Variable control of Ets-1 DNA binding by multiple phosphates in an unstructured region. Science 309:142-45 CrossRef
17. Maglione D, Guerriero V, Viglietto G, Dellibovi P, Persico M (1991) Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 88:9267-271 CrossRef
18. Fischer C, Jonckx B, Mazzone M et al (2007) Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131:463-75 CrossRef
19. Van de Veire S, Stalmans I, Heindryckx F et al (2010) Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 141:178-90 CrossRef
20. Tang Z, Varghese R, Bekesova S et al (2010) Identification of / N-glycan serum markers associated with hepatocellular carcinoma from mass spectrometry data. J Proteome Res 9:104-12 CrossRef
21. Heindryckx F, Mertens K, Charette N et al (2010) Kinetics of angiogenic changes in a new mouse model for hepatocellular carcinoma. Mol Cancer 9:219-32 CrossRef
22. Laroy W, Contreras R, Callewaert N (2006) Glycome mapping on DNA sequencing equipment. Nat Protoc 1:397-05 CrossRef
23. Blomme B, Van Steenkiste C, Callewaert N, Van Vlierberghe H (2011) Alterations of serum protein / N-glycosylation in two models of chronic liver disease are hepatocyte and not B cell driven. Am J Physiol Gastrointest Liver Physiol 300:G833–G842 CrossRef
24. Blomme B, Van Steenkiste C, Vanhuysse J, Colle I, Callewaert N, Van Vlierberghe H (2010) Impact of elevation of total bilirubin level and etiology of the liver disease on serum / N-glycosylation patterns in mice and humans. Am J Physiol Gastrointest Liver Physiol 298:G615–G624 CrossRef
25. Klein A, Carre Y, Louvet A, Michalski JC, Morelle W (2010) Immunoglobulins are the major glycoproteins involved in the modifications of total serum / N-glycome in cirrhotic patients. Proteomics Clin Appl 4:379-93 CrossRef
26. Vanderschaeghe D, Laroy W, Sablon E et al (2009) GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer-based serum protein glycomics. Mol Cell Proteomics 8:986-94 CrossRef
27. Liu XE, Dewaele S, Vanhooren V et al (2010) Alteration of / N-glycome in diethylnitrosamine-induced hepatocellular carcinoma mice: a non-invasive monitoring tool for liver cancer. Liver Int 30:1221-228 CrossRef
28. Ito Y, Miyoshi E, Takeda T et al (2000) Expression and possible role of ets-1 in hepatocellular carcinoma. Am J Clin Pathol 114:719-25 CrossRef
29. Vanderschaeghe D, Szekrényes A, Wenz C et al (2010) High-throughput profiling of the serum / N-glycome on capillary electrophoresis microfluidics systems: towards clinical implication of the GlycoHepatoTest. Anal Chem 82:7408-415 CrossRef
30. Takamatsu S, Antonopoulos A, Ohtsubo K et al (2010) Physiological and glycomic characterization of / N-acetylglucosaminyltransferase-IVa and -IVb double deficient mice. Glycobiology 20:485-97 CrossRef
31. Mendoza R, Moody E, Enriquez M, Mejia S, Thordarson G (2011) Tumorigenicity of MCF-7 human breast cancer cells lacking the p38α mitogen-activated protein kinase. J Endocrinol 208:11-9 CrossRef
32. Hsu Y, Meng X, Ou L, Ip M (2010) Activation of the AMP-activated protein kinase-p38 MAP kinase pathway mediates apoptosis induced by conjugated linoleic acid in p53-mutant mouse mammary tumor cells. Cell Signal 22:590-99 CrossRef
33. Hui L, Bakiri L, Stepniak E, Wagner E (2007) P38 alpha: a suppressor of cell proliferation and tumorigenesis. Cell Cycle 6:2429-433 CrossRef
34. Hui L, Bakiri L, Mairhorfer A et al (2007) P38 alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet 39:741-49 CrossRef
35. McMullen M, Bryant P, Glembotski C, Vincent P, Pumiglia K (2005) Activation of p38 has opposing effects on the proliferation and migration of endothelial cells. J Biol Chem 280:20995-1003 CrossRef
36. Issbrücker K, Marti H, Hippenstiel S (2003) p38 MAP kinase—a molecular switch between VEGF-induced angiogenesis and vascular permeability. FASEB J 17:262-64
37. Luttun A, Brusselmans K, Fukao H et al (2002) Loss of placental growth factor protects mice against vascular permeability in pathological conditions. Biochem Biophys Res Commun 295:428-34 CrossRef
38. Vetter M, Blumenthal S, Lindemann R (2005) Ets1 is an effector of protein kinase Cα in cancer cells. Oncogene 24:650-61 CrossRef - 作者单位：Bram Blomme (1)
Femke Heindryckx (1)
Jean Marie Stassen (2)
Anja Geerts (1)
Isabelle Colle (1)
Hans Van Vlierberghe (1)
1. Department of Hepatology and Gastroenterology, Ghent University Hospital, 9000, Ghent, Belgium
2. ThromboGenics NV, Leuven, Belgium - ISSN：1573-4919
文摘
Placental growth factor (PlGF) inhibition produced promising results in reducing tumor burden in a diethylnitrosamine (DEN)-induced mouse model for hepatocellular carcinoma (HCC). The aim of this study was to non-invasively assess the improved histology by performing a serum glycomic analysis. To elucidate the molecular mechanism underlying the observed glycomic effects, we investigated the transcription and expression of E26 transformation-specific sequence 1 (Ets-1), a transcription factor essential for the glycomic and angiogenic changes in malignant transformation, including its different phosphorylated forms that result from activation of the MAP kinase and a Ca2+-dependent pathway. In addition, three Ets-1-dependent glycosyltransferase genes, Mgat4a, Mgat4b, and Mgat5, were also evaluated. HCC was induced in mice by weekly injections with DEN for 16, 20, 25, and 30?w. In the treatment study, mice were injected with DEN for 25?w and subsequently treated with PlGF antibodies (5D11D4) for 5?w. Finally, PlGF??mice were injected with DEN for 20, 25, and 30?w. Serum N-glycans were analyzed with DNA sequencer-assisted fluorophore-assisted capillary electrophoresis and compared with histology. Maximum altered N-glycan phenotype was reached after 20?w of DEN-injections, i.e., when the first neoplastic lesions started to appear. 5D11D4-treatment improved the glycomic phenotype in that 7 of the 11 altered glycans tended to normalize. The PlGF??mice also showed a normalization trend, although not to the same extent of the treatment group. Number of Ets1, Mgat4a, Mgat4b, and Mgat5 transcripts increased considerably in DEN-injected mice, however, a non-significant decrease was observed after 5D11D4-treatment. On the protein level, 5D11D4-treatment had a prominent effect on the MAP kinase pathway with a significant p38 activation, yet independent of Ets-1 function.